Whitehawk Therapeutics Inc. (WHWK) Q4 2024 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary presents a mixed outlook. Positive aspects include strategic shifts towards ADC therapies and a solid cash position expected to fund operations until 2028. However, significant net losses and increased R&D expenses indicate financial strain. The Q&A highlights management's lack of precise data on ADCs, raising concerns about operational transparency. Given these factors, the stock price is likely to remain stable, resulting in a neutral prediction.
Key Financial Performance
Cash and Cash Equivalents $47.2 million, expected to increase to $170 million to $180 million following strategic transactions.
FYARRO Net Product Sales (Q4) $7.2 million, representing a 14% growth over the prior year quarter.
FYARRO Net Product Sales (Full Year) $26 million, an increase of 7% over 2023.
Research and Development Expenses (Q4) $14.3 million, compared to $12.8 million in the prior year quarter.
Research and Development Expenses (Full Year) $51 million, compared to $48.9 million last year.
Selling, General and Administrative Expenses (Q4) $11.1 million, compared to $10.3 million in the same period in 2023.
Selling, General and Administrative Expenses (Full Year) $36.7 million, compared to $44.5 million in the prior year.
Net Loss (Q4) $18.3 million, compared to $16.3 million in the fourth quarter of 2023.
Net Loss (Full Year) $63.7 million, compared to $65.8 million in the prior year.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New Products: Whitehawk Therapeutics is advancing three ADC candidates: HWK-007 targeting PTK7, HWK-016 targeting MUC16, and HWK-206 targeting SEZ6, with IND submissions planned within the next 15 months.
Market Expansion: The company is transitioning from Aadi Biosciences to Whitehawk Therapeutics, focusing on a multi-asset ADC portfolio aimed at various cancer populations.
Operational Efficiencies: The company reported cash and equivalents expected to be between $170 million to $180 million post-strategic transactions, which will fund operations into 2028.
Strategic Shifts: The divestiture of FYARRO to Kaken Pharmaceuticals and the in-licensing of three ADCs from Wuxi Biologics mark significant strategic shifts for the company.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Risks: The company acknowledges that actual events or results could differ materially from forward-looking statements due to various risks, uncertainties, and factors, including those outlined in their SEC filings.
Financial Risks: The company reported a net loss of $18.3 million for Q4 2024 and a total net loss of $63.7 million for the year, indicating ongoing financial challenges.
Operational Risks: The increase in research and development expenses to $14.3 million in Q4 2024, driven by in-process R&D expenses related to newly acquired ADC programs, suggests potential operational strain.
Market Competition: The company faces competition in the ADC space, particularly with AbbVie having the only SEZ6 ADC currently in development, which could impact market positioning.
Supply Chain Challenges: The transition from Aadi Biosciences to Whitehawk Therapeutics and the in-licensing of ADCs from Wuxi Biologics may introduce supply chain complexities.
Economic Factors: The company’s financial outlook is contingent on the successful execution of their strategic transactions and the ability to fund operations into 2028, which may be affected by broader economic conditions.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Strategic Transactions: In December, Whitehawk Therapeutics announced a series of strategic transactions, including the in-licensing of 3 ADCs from Wuxi Biologics and the divestiture of FYARRO to Kaken Pharmaceuticals.
Focus on ADCs: Whitehawk is transitioning to focus on a multi-asset portfolio of advanced ADC therapies, moving away from its previous single product focus.
IND Submissions: The company plans to submit INDs for all three ADC candidates within the next 15 months.
Advanced ADC Technology: Whitehawk is utilizing an advanced ADC platform technology designed to improve therapeutic index and minimize off-target toxicity.
Cash Position: Whitehawk ended 2024 with $47.2 million in cash and expects to have between $170 million to $180 million post-strategic transactions.
Funding Operations: The company anticipates that its cash will fund operations into 2028 based on current plans.
FYARRO Sales Growth: FYARRO net product sales were $7.2 million for Q4 2024, representing a 14% growth year-over-year.
R&D Expenses: Research and development expenses for Q4 increased to $14.3 million, with a full-year total of $51 million.
Net Loss: Net loss for Q4 was $18.3 million, with a full-year net loss of $63.7 million.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Cash and Cash Equivalents: $47.2 million at the end of 2024, expected to increase to $170 million to $180 million after strategic transactions.
FYARRO Net Product Sales: $7.2 million for Q4 2024, representing a 14% growth over the prior year.
Full Year FYARRO Sales: $26 million, an increase of 7% over 2023.
Net Loss for Q4 2024: $18.3 million compared to $16.3 million in Q4 2023.
Net Loss for Full Year 2024: $63.7 million compared to $65.8 million in the prior year.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How do you anticipate that the clinical activity and safety profile of your ADC might compare to the bispecific approach within this indication?
A:ADCs and bispecific TCEs are very different modalities in terms of their mechanism. Both are complementary options for patient treatment, but we don't have a direct comparison to highlight.
Q:Could you help us understanding about the distribution of the high, medium, low expression levels for each of these three targets?
A:PTK7 is broadly overexpressed in many cancers, with a high proportion of patients expressing it at moderate to high levels. MUC16 increases as the disease progresses, allowing us to target patients in need. SEZ6 is highly expressed in small cell lung cancer.
Q:Does the 2028 runway cover all the three Phase 1 studies?
A:Our goal is to get meaningful clinical Phase 1 data for all three programs under the current funding, with slightly different amounts of data for each program.
Q:Review of Unclear Management Responses
A:Management did not provide a direct comparison between ADCs and bispecific TCEs, and the response regarding the distribution of expression levels lacked specific numerical data.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ADC platform
ADCs
Aadi
FYARRO
HWK
INDs
MUC
PTK
Phase trial
SEZ
Slide
Whitehawk Therapeutics
candidate
cash
cell lung
conference
development
dose
efficacy
example
generation
improvement
index
indication
lung cancer
opportunity
patient
payload
portfolio
potential
program
protein
rate
response
statement
switch
target
technology
today
tumor
WHWK Transcript
Whitehawk Therapeutics, Inc. (WHWK) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Neutral9-8
Whitehawk Therapeutics Inc. (WHWK) Q4 2024 Earnings Call Transcript
Unknown3-19
The earnings call summary presents a mixed outlook. Positive aspects include strategic shifts towards ADC therapies and a solid cash position expected to fund operations until 2028. However, significant net losses and increased R&D expenses indicate financial strain. The Q&A highlights management's lack of precise data on ADCs, raising concerns about operational transparency. Given these factors, the stock price is likely to remain stable, resulting in a neutral prediction.
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
